Asymptomatic Carotid Artery StenosisACTRISNCT02841098
" Endarterectomy Combined With Optimal Medical Therapy (OMT) vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "
A study testing Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) and Optimal medical therapy alone in people with Asymptomatic Carotid Artery Stenosis, run by Centre Hospitalier St Anne at 23 sites in France.
Trial summary
The purpose of this study is to determine whether carotid surgery combined with optimal medical therapy improves long-term survival free of ipsilateral stroke in patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke when compared with optimal medical therapy alone. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Asymptomatic Carotid Artery Stenosis
- What is being tested?
- Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) and Optimal medical therapy alone
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 43 participants
- Where
- 23 sitesFrance
- Study dates
- 16 Sep 2019to 13 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 50 years or over
- No ipsilateral stroke or TIA within 180 days of randomization
- Atherosclerotic carotid stenosis between 70 and 99% (NASCET method)
- At least one of the following markers of ipsilateral stroke risk:
- Silent brain infarction on MRI, DWi, consistent with embolism from or hemodynamic consequences of the qualifyiing stenosis
- History of contralateral TIA or ischemic stroke due to atherosclerotic carotid disease
Show all 13Show fewer
- Predominantly echolucent plaque on ultrasound
- Rapid (within 1 year) carotid stenosis progresion
- TCD-detected microembolic signals
- Impairment of TCD-measured cerebral vasomotor reserve
- Intraplaque haemorrhage on magnetic resonance imaging
- Rapid and severe stenosis progression
- Patient is able and willing to give informed consent
Who cannot join
- Previous revascularization procedure in the artery to be randomised
- Patients not suitable for endarterectomy due to anatomical factors
- Carotid stenosis caused by non-atherosclerotic disease e.g. neck radiotherapy or fibromuscular disease
- Patients who have had contralateral carotid artery or vertebral artery or intracranial artery revascularisation within 6 weeks prior to randomisation
- Patients with planned revascularisation of the contralateral carotid artery or a vertebral artery or an intracranial artery within 6 weeks after randomisation or the date of CEA
- Patients who have had coronary artery bypass grafting within 3 months prior to randomisation or other major surgery within 6 weeks prior to randomisation
Show all 13Show fewer
- Patients with planned coronary artery bypass grafting or other major surgery within 6 weeks after CEA of the artery considered for treatment in the trial
- Patients with pre-existing disability (modified Rankin score greater than 2)
- Patients who have a low 5-year life expectancy (see appendix for definition)
- Patients intolerant or allergic to all of the medications available for OMT
- Patients in clinical trials of investigational medicinal products or who have been in clinical trials within the last 4 months will not be enrolled unless otherwise agreed
- Patients who are known to be pregnant
- Patients unwilling or unable to participate in follow-up
Trial locations and contacts
23 sites in 1 country.
23 sites in 1 country
France23 sites
Centre Hospitalier régional de Besançon, Hôpital Jean Minjoz
Besançon, 25030
CHU Bordeaux, Groupe Hospitalier Pellegrin
Bordeaux, 33076
CHRU La Cavale Blanche
Brest, 29200
Hôpital Gabriel Montpied
Clermont-Ferrand, 63003
CHU Henri Mondor
Créteil, 94010
CHU Dijon-Bourgogne
Dijon, 21079
CHU de Grenoble
Grenoble, 38043
Hôpital Mignot - CH Versailles
Le Chesnay, 78150
CHRU de Lille
Lille, 59037
Hôpital Neurologique Pierre Wertheimer GHE
Lyon, 69677
Hôpital Gui de Chauliac
Montpellier, 34 295
CHU de Nice, Hôpital Pasteur 2
Nice, 06000
Hôpital Lariboisière
Paris, 75010
Hôpital Saint-Antoine
Paris, 75012
Groupe Hospitalier Pitié-Salpétrière
Paris, 75013
Centre Hospitalier Sainte-Anne
Paris, 75014
Centre Hospitalier Bichat-Claude Bernard
Paris, 75018
CHU La Milétrie
Poitiers, 86021
Hôpital Pontchaillou CHU Rennes
Rennes, 35033
CHU de Rouen, Hôpital Charles Nicolle
Rouen, 76031
Hôpital Nord CHU Saint-Etienne
Saint-Etienne, 42055
CHU de Strasbourg, Hôpital de Hautpierre
Strasbourg, 67098
CHU de Toulouse Hôpital Pierre-Paul Riquet
Toulouse, 31059
About this study
Official title: " Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "
The purpose of this study is to determine whether carotid surgery combined with optimal medical therapy improves long-term survival free of ipsilateral stroke in patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke when compared with optimal medical therapy alone.
Read the detailed description
Carotid artery stenosis >= 50% affects about 3% of subjects >= 60 years and accounts for up to 15% of all ischemic strokes. Overall, patients with asymptomatic carotid stenosis have a low risk of ipsilateral stroke on modern medical therapy. It is therefore uncertain whether the benefit of carotid surgery still justifies the perioperative risk of stroke or death, and whether revascularisation is good value for money considering competing demands on health services. Several imaging techniques have been developed to identify patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke. Specifically, the presence of transcranial Doppler (TCD)-detected embolic signals, intraplaque haemorrhage on magnetic resonance imaging, TCD-measured impaired cerebral vasomotor reserve or rapid stenosis progression have all been shown to involve an at least 3-fold higher risk of ipsilateral stroke. However, before recommendations for clinical practice can be made regarding the use of these tools, their utility must be demonstrated in a formal randomised clinical trial. Our hypothesis is that the use of these predictors can identify a subset of patients with asymptomatic carotid stenosis who could benefit from prophylactic endarterectomy.
Carotid endarterectomy The procedure will be carried out with the technique routinely used by each surgeon. Operative reports and perioperative complications will be collected. CEA will have to be performed as soon as possible, within 60 days after randomization.
Optimal medical therapy OMT will be applied to all patients and started immediately after randomisation.
OMT will be defined by the adhoc committee and follow relevant guidelines. It will include:
- Antiplatelet therapy. If the patient requires anticoagulation for any reason (e.g. atrial fibrillation), the patient should be treated with an appropriate anticoagulant according to the practice at the centre as an alternative to antiplatelet therapy.
- Antihypertensive treatment, if required, to achieve a target blood pressure < 140/90 mmHg (higher targets may be defined by the OMT committee for selected conditions, e.g. contralateral carotid occlusion) Application of structured programs, such as stepped-care approach using ranking of antihypertensive drugs will be used.
- High-dose statin treatment (target LDL < 0.7 g/l). A stepped-care approach with raking of lipid-lowering drugs will also be used.
- Patients smoking at the time of randomisation will be encouraged to stop and join a smoking cessation and support program.
- Other lifestyle modification: reduction of alcohol consumption, choosing healthy food, increasing regular physical activity, reduction of body weight if relevant.
OMT may be modified during the course of the trial to take account revised guidelines or new evidence.
- Conditions
- Asymptomatic Carotid Artery Stenosis
- Being tested
- Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT), Optimal medical therapy alone
- Keywords
- Carotid stenosis,stroke,endarterectomy,medical therapy
- Medical subject headings
- Carotid Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)Other
Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
Optimal medical therapy aloneDrug
Optimal medical therapy alone
| Study group | Role | What they receive |
|---|---|---|
| Carotid endarterectomy combined with optimal medical therapy | Experimental | Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) Receives: Other: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) |
| Optimal medical therapy (OMT) | Active comparator | Optimal medical therapy (OMT) Receives: Drug: Optimal medical therapy alone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ipsilateral stroke or procedural stroke or death
Any ipsilateral stroke within 6 years after randomization or procedural (within 30 days after revascularization) stroke or death
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Secondary outcomes (19)
Any stroke or procedural death
Any stroke within 6 years after randomization or procedural death (within 30 days after revascularization)
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any disabling or fatal stroke or procedural death
Any disabling or fatal stroke within 6 years after randomization or procedural death (within 30 days after revascularization)
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any stroke or TIA or procedural death
Any stroke or TIA within 6 years after randomization or procedural death within 6 years after randomization
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any stroke or death
Any stroke or death within 6 years after randomization
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Myocardial infarction
Myocardial infarction within 6 years after randomization
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any death
Any death within 6 years after randomization
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Cardiovascular death
Cardiovascular death within 6 years after randomization
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any hospitalisation for vascular disease
Any hospitalisation for vascular disease within 6 years after randomization
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Cranial nerve palsy attributed to revascularisation
Cranial nerve palsy attributed to revascularisation within 30 days after revascularization
Measured: M1
Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay
Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay within 30 days after revascularization
Measured: M1
Further revascularisation of the randomised artery after the initial attempt.
Further revascularisation of the randomised artery after the initial attempt.
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Carotid revascularisation
Carotid revascularisation during follow-up other than that allocated at randomisation
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
New cerebral infarction or haemorrhage
New cerebral infarction or haemorrhage on MRI at 2 years
Measured: M24
Increase in white-matter changes
Increase in white-matter changes on MRI at 2 years.
Measured: M0, M24
Cognitive impairment
Cognitive impairment assessed by the Montreal Cognitive Assessment (MoCA) with adjustment for demographic factors.
Measured: M0, M24
Depression
Depression measured by the Centre for Epidemiologic Studies Depression (CES-D) Scale.
Measured: M0, M24
Health-related quality of life
Health-related quality of life measured using the European Quality Of Life (EQ-5D).
Measured: M0, M24
Disability
Disability measured by the modified Rankin scale with structured interview
Measured: M0, M24
Achievement of goals for each of the components of optimal medical treatment
Achievement of goals for each of the components of optimal medical treatment
Measured: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2016 (estimated)
- Study start16 Sep 2019
- Primary completion13 Jan 2022
- Study completion13 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Asymptomatic Carotid Artery StenosisStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier St AnneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier St Anne
- Sponsor type
- University, hospital or other
- Collaborators
- Hôpitaux Universitaires Paris Ile-de-Franc Ouest
- Responsible party
- Sponsor
- Investigators
- Jean-Louis MAS, Study director, CHSA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02841098
- Sponsor's protocol ID
- D15-P010
- Acronym
- ACTRIS
- Status last verified
- Jul 2024
- First submitted
- 19 Jul 2016
- Last updated
- 11 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- " Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "
- ClinicalTrials.gov ID
- NCT02841098
- Acronym / sponsor ID
- ACTRIS / D15-P010
- Conditions
- Asymptomatic Carotid Artery Stenosis
- Keywords
- Carotid stenosis,stroke,endarterectomy,medical therapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- Centre Hospitalier St AnneUniversity, hospital or other
- Collaborators
- Hôpitaux Universitaires Paris Ile-de-Franc Ouest
- Study start
- 16 Sep 2019 (actual)
- Primary completion
- 13 Jan 2022 (actual)
- Study completion
- 13 Jan 2022 (actual)
- First posted
- 22 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether carotid surgery combined with optimal medical therapy improves long-term survival free of ipsilateral stroke in patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke when compared with optimal medical therapy alone.
Detailed description
Carotid artery stenosis >= 50% affects about 3% of subjects >= 60 years and accounts for up to 15% of all ischemic strokes. Overall, patients with asymptomatic carotid stenosis have a low risk of ipsilateral stroke on modern medical therapy. It is therefore uncertain whether the benefit of carotid surgery still justifies the perioperative risk of stroke or death, and whether revascularisation is good value for money considering competing demands on health services. Several imaging techniques have been developed to identify patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke. Specifically, the presence of transcranial Doppler (TCD)-detected embolic signals, intraplaque haemorrhage on magnetic resonance imaging, TCD-measured impaired cerebral vasomotor reserve or rapid stenosis progression have all been shown to involve an at least 3-fold higher risk of ipsilateral stroke. However, before recommendations for clinical practice can be made regarding the use of these tools, their utility must be demonstrated in a formal randomised clinical trial. Our hypothesis is that the use of these predictors can identify a subset of patients with asymptomatic carotid stenosis who could benefit from prophylactic endarterectomy.
Carotid endarterectomy The procedure will be carried out with the technique routinely used by each surgeon. Operative reports and perioperative complications will be collected. CEA will have to be performed as soon as possible, within 60 days after randomization.
Optimal medical therapy OMT will be applied to all patients and started immediately after randomisation.
OMT will be defined by the adhoc committee and follow relevant guidelines. It will include:
- Antiplatelet therapy. If the patient requires anticoagulation for any reason (e.g. atrial fibrillation), the patient should be treated with an appropriate anticoagulant according to the practice at the centre as an alternative to antiplatelet therapy.
- Antihypertensive treatment, if required, to achieve a target blood pressure < 140/90 mmHg (higher targets may be defined by the OMT committee for selected conditions, e.g. contralateral carotid occlusion) Application of structured programs, such as stepped-care approach using ranking of antihypertensive drugs will be used.
- High-dose statin treatment (target LDL < 0.7 g/l). A stepped-care approach with raking of lipid-lowering drugs will also be used.
- Patients smoking at the time of randomisation will be encouraged to stop and join a smoking cessation and support program.
- Other lifestyle modification: reduction of alcohol consumption, choosing healthy food, increasing regular physical activity, reduction of body weight if relevant.
OMT may be modified during the course of the trial to take account revised guidelines or new evidence.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Carotid endarterectomy combined with optimal medical therapy | Experimental | Other: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) |
| Optimal medical therapy (OMT) | Active comparator | Drug: Optimal medical therapy aloneOptimal medical therapy (OMT) |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Age 50 years or over
- No ipsilateral stroke or TIA within 180 days of randomization
- Atherosclerotic carotid stenosis between 70 and 99% (NASCET method)
- At least one of the following markers of ipsilateral stroke risk:
- Patient is able and willing to give informed consent
Key exclusion criteria (13 listed)
- Previous revascularization procedure in the artery to be randomised
- Patients not suitable for endarterectomy due to anatomical factors
- Carotid stenosis caused by non-atherosclerotic disease e.g. neck radiotherapy or fibromuscular disease
- Patients who have had contralateral carotid artery or vertebral artery or intracranial artery revascularisation within 6 weeks prior to randomisation
- Patients with planned revascularisation of the contralateral carotid artery or a vertebral artery or an intracranial artery within 6 weeks after randomisation or the date of CEA
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug) | Other | Carotid endarterectomy combined with optimal medical therapy |
| Optimal medical therapy aloneOptimal medical therapy alone | Drug | Optimal medical therapy (OMT) |
Primary outcome
Ipsilateral stroke or procedural stroke or death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any ipsilateral stroke within 6 years after randomization or procedural (within 30 days after revascularization) stroke or death
19 secondary outcomes
Any stroke or procedural death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any disabling or fatal stroke or procedural death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any stroke or TIA or procedural death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any stroke or death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Myocardial infarction
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Cardiovascular death
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Any hospitalisation for vascular disease
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Cranial nerve palsy attributed to revascularisation
Time frame: M1
Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay
Time frame: M1
Further revascularisation of the randomised artery after the initial attempt.
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Carotid revascularisation
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
New cerebral infarction or haemorrhage
Time frame: M24
Increase in white-matter changes
Time frame: M0, M24
Cognitive impairment
Time frame: M0, M24
Depression
Time frame: M0, M24
Health-related quality of life
Time frame: M0, M24
Disability
Time frame: M0, M24
Achievement of goals for each of the components of optimal medical treatment
Time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Asymptomatic Carotid Artery Stenosis
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Not yet recruiting
CEST-PROTECT: Proximal Flow Control With a Balloon Guide Catheter Plus Distal Embolic Protection: a Randomised, Open-label Trial Evaluating Cerebral Protection Techniques
Carotid Artery Stenosis (Symptomatic and Asymptomatic)
Active, not recruitingObservational study
Florida Cerebrovascular Disease Biorepository and Genomics Center
Cerebrovascular Disease, Ischemic Stroke
RecruitingObservational study
Comparison Between Non-contrast Magnetic Resonance Angiography and Carotid Doppler in Cerebrovascular Stroke
Ischemic Stroke, Transient Ischemic Attack
Not yet recruiting
Evaluation of Balloon Guide Catheter as Proximal Protection During Carotid Artery Stenting (EMBO-PROTECT)
Carotid Artery Stenosis (Symptomatic and Asymptomatic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jean-Louis MAS study director
CHSA
23 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) and Optimal medical therapy alone in people with Asymptomatic Carotid Artery Stenosis, run by Centre Hospitalier St Anne at 23 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 23 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ipsilateral stroke or procedural stroke or death (time frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2024.